AACR 2026
Elisrasib Demonstrates High DCR in KRAS G12C+ NSCLC
Elisrasib, a next-generation KRAS G12C inhibitor, demonstrated disease control in a majority of patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), whether exposed to a prior KRAS G12C...
Zoldonrasib May Be Safe and Effective in Patients With KRAS G12D+ NSCLC Previously Treated With Chemoimmunotherapy
The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were previou...
Thi Van Trinh Tran, PhD, on the Histopathology of Lung Cancer in Neversmokers
Thi Van Trinh Tran, PhD, of the National Cancer Institute, describes histologic and prognostic findings from the largest cohort of lung cancer in people who have never smoked. Tumor-infiltrating lymph...
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
Patients with advanced platinum-resistant ovarian cancer who had experienced disease progression on standard therapy exhibited clinical benefit when treated with the investigational antibody-drug conj...
